• 1
    International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990; 335: 107880.
  • 2
    Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneokah H, et al. Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA–B51 transgenic mice. Arthritis Rheum 1995; 38: 42632.
  • 3
    Ziehrut M, Ohno S. Immunology of Behcet's disease. Lisse (The Netherlands): Swets & Zeitlinger; 2003.
  • 4
    Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 44350.
  • 5
    Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behcet disease with pentoxifylline. Ann Intern Med 1996; 124: 8913.
  • 6
    Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002; 61 Suppl 2: 513.
  • 7
    Lee EB, Kim JY, Lee YJ, Park MH, Song YW. TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. Hum Immunol 2003; 64: 61420.
  • 8
    Toro JR, Aksentijevich I, Hull K, Dean J, Kastner DL. Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch Dermatol 2000; 136: 148794.
  • 9
    Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81: 34968.
  • 10
    Dodé C, André M, Bienvenu T, Hausfater P, Pêcheux C, Bienvenu J, et al. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor–associated periodic syndrome. Arthritis Rheum 2002; 46: 21818.
  • 11
    Poirier O, Nicaud V, Gariepy J, Courbon D, Elbaz A, Morrison C, et al. Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness: the ECTIM, AXA, EVA and GENIC studies. Eur J Hum Genet 2004; 12: 2139.
  • 12
    Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-α. J Clin Invest 2003; 112: 158996.
  • 13
    Orem A, Vanizor B, Cimsit G, Kiran E, Deger O, Malkoc M. Decreased nitric oxide production in patients with Behcet's disease. Dermatology 1999; 198: 336.
  • 14
    Orem A, Erturk M, Cimsit G, Kural BV. Effect of plasma from patients with Behcet's disease on the production of nitric oxide in cultured human umbilical vein endothelial cells. Med Princ Pract 2004; 13: 358.
  • 15
    Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome. J Am Coll Cardiol 2001; 37: 51720.